Patents by Inventor Lars-Peter Erwig

Lars-Peter Erwig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12247067
    Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: March 11, 2025
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
    Inventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
  • Publication number: 20220204595
    Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.
    Type: Application
    Filed: March 15, 2022
    Publication date: June 30, 2022
    Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
    Inventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
  • Patent number: 11306138
    Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: April 19, 2022
    Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
    Inventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
  • Publication number: 20180037640
    Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 8, 2018
    Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
    Inventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen